Schneider Eugene
EVP, Chf Clinical Develop Ofcr
Schneider Eugene has filed 5 SEC Form 4 filings (10 transaction rows) across 1 company, with disclosures dating back to 2025. 4 of those filings fall inside the rolling window. Most recent filing: Jun 30, 2026.
On the most recent filing, Schneider Eugene is listed as EVP, Chf Clinical Develop Ofcr at IONIS PHARMACEUTICALS INC. Inside the rolling window, Schneider Eugene reported no open-market purchases and 4 open-market sales totaling $3.7M in IONS. The largest disclosed transaction in the window is a sale of 26,000 IONS shares on Jun 26, 2026, worth $2.1M.
Companies traded
Other insiders at IONS
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$3.7M
reported sales (SEC code S)
Companies
1
in the rolling window
Earlier trades
Open-market purchases and sales filed before the rolling 365-day window, kept from the original Form 4 filings.
Frequently asked questions
How many SEC Form 4 filings has Schneider Eugene made?
Schneider Eugene has filed 5 SEC Form 4 filings (10 transaction rows) across 1 company since 2025.
Which companies does Schneider Eugene trade?
Schneider Eugene has filed SEC Form 4 disclosures for 1 company, including IONS.
When was Schneider Eugene's most recent SEC Form 4 filing?
Schneider Eugene's most recent SEC Form 4 filing on Tracefour is dated Jun 30, 2026.
What is Schneider Eugene's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Schneider Eugene is listed as EVP, Chf Clinical Develop Ofcr.
What is Schneider Eugene's total buy and sell value in the current window?
Inside the rolling retention window, Schneider Eugene bought $0 and sold $3.7M based on SEC Form 4 filings.
What was Schneider Eugene's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 26,000 IONS shares on 2026-06-26, worth $2.1M, per SEC Form 4 filings.